Phase III DELIVER trial results for Farxiga showing benefits in heart failure published in NEJM.- AstraZeneca
Farxiga reduced the composite outcome of CV death or worsening of HF by 18% (p<0.001, 16.4% in the dapagliflozin group and 19.5% in the placebo group over a median follow-up of 2.3 years). all individual components contributed to the superiority of the primary endpoint. the findings were consistent across key subgroups examined and extend the benefits of farxiga to the full spectrum of patients with hf irrespective of left ventricular ejection fraction (lvef) status.></0.001,>
The trial results also showed a symptom benefit in patient-reported outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score. The safety and tolerability profile of Farxiga in the DELIVER Phase III trial was consistent with the well-established safety profile of the medicine. The results were presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain, and simultaneously published in The New England Journal of Medicine.
See: "Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction." Solomon S, et al. N Engl J Med 2022 Aug 27 www.nejm.org/doi/full/10.1056/NEJMoa2206286
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins